Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer

  • Authors:
    • Keiichi Ito
    • Shigeyoshi Soga
    • Kenji Seguchi
    • Yusuke Shinchi
    • Ayako Masunaga
    • Shinsuke Tasaki
    • Kenji Kuroda
    • Akinori Sato
    • Junichi Asakuma
    • Akio Horiguchi
    • Hiroshi Shinmoto
    • Tatsumi Kaji
    • Tomohiko Asano
  • View Affiliations

  • Published online on: May 26, 2017     https://doi.org/10.3892/ol.2017.6262
  • Pages: 918-924
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Partial nephrectomy is the treatment of choice for small renal cell carcinoma (RCC) from the perspective of cancer management and renal function. However, when patients with RCC are of advanced age, exhibit severe comorbidities, including cardiovascular and pulmonary diseases, or have hereditary RCC, ablative therapies, including radiofrequency ablation (RFA) and cryoablation are useful treatment options. In the present study, the clinical outcomes of percutaneous RFA for treating small RCC were evaluated. Between December 2005 and March 2015, 40 patients (41 renal tumors in total) underwent RFA and a total of 50 sessions of RFA were performed. The average tumor size was 2.5 cm. A total of 18 tumors were exophytic and 23 were parenchymal. Of the 41 tumors, 85.4% were completely ablated by initial RFA and the rate of complete ablation following reablation for residual viable lesions was 95.1%. Local recurrence‑free survival following complete ablation was 84.2% at 3 years. A patient with a 4.7 cm RCC tumor rapidly progressed following four RFA treatments until complete ablation was achieved. The metastasis‑free survival rate following initial RFA was 95.7% at 3 years. The RCC‑specific survival was 100% (mean follow‑up, 38 months). Adverse events occurred in five sessions (10%); however, only 1 patient with arteriovenous fistula required intervention (transarterial embolization). The mean hospital stay following RFA was 3.2 days. The mean decrease in estimated glomerular filtration rate following RFA was 2.7%. The results of the present study indicate that percutaneous RFA was an effective treatment for small RCCs with respect to management of cancer, minimal invasiveness and minimal loss of renal function, particularly in patients for whom surgery would be a high risk and those at increased risk of deterioration of renal function.
View Figures
View References

Related Articles

Journal Cover

July-2017
Volume 14 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ito K, Soga S, Seguchi K, Shinchi Y, Masunaga A, Tasaki S, Kuroda K, Sato A, Asakuma J, Horiguchi A, Horiguchi A, et al: Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer. Oncol Lett 14: 918-924, 2017
APA
Ito, K., Soga, S., Seguchi, K., Shinchi, Y., Masunaga, A., Tasaki, S. ... Asano, T. (2017). Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer. Oncology Letters, 14, 918-924. https://doi.org/10.3892/ol.2017.6262
MLA
Ito, K., Soga, S., Seguchi, K., Shinchi, Y., Masunaga, A., Tasaki, S., Kuroda, K., Sato, A., Asakuma, J., Horiguchi, A., Shinmoto, H., Kaji, T., Asano, T."Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer". Oncology Letters 14.1 (2017): 918-924.
Chicago
Ito, K., Soga, S., Seguchi, K., Shinchi, Y., Masunaga, A., Tasaki, S., Kuroda, K., Sato, A., Asakuma, J., Horiguchi, A., Shinmoto, H., Kaji, T., Asano, T."Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer". Oncology Letters 14, no. 1 (2017): 918-924. https://doi.org/10.3892/ol.2017.6262